利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.04 秒)

    Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors
    3.
    发明授权
    Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors 失效
    羟肟酸化合物可用作基质金属蛋白酶抑制剂

    公开(公告)号：US06677355B1

    公开(公告)日：2004-01-13

    申请号：US10049544

    申请日：2002-02-13

    申请人： Christopher Alan Conrad ,  Patrick Michael O'Brien ,  Daniel Fred Ortwine ,  Joseph Armand Picard ,  Drago Robert Sliskovic

    发明人： Christopher Alan Conrad ,  Patrick Michael O'Brien ,  Daniel Fred Ortwine ,  Joseph Armand Picard ,  Drago Robert Sliskovic

    IPC分类号： C07D30791

    CPC分类号： C07D307/91 ,  C07C311/19 ,  C07C311/20 ,  C07C2601/08 ,  C07C2601/14 ,  C07D307/93 ,  C07D407/12

    摘要： Compounds of the formula; are useful for inhibiting matrix metalloproteinase enzymes in animals, and as such, prevent and treat diseases resulting from the breakdown of connective tissues. Also disclosed are methods for the preparation of such compounds, pharmaceutical compositions including the same, and methods of treating diseases in which matrix metalloproteinases are involved including multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurysm, heart failure, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, osteoporosis, rheumatoid or osteoarthritis, renal disease, left ventricular dilation, or other autoimmune or inflammatory diseases dependent upon tissue invasion by leukocytes.

    摘要翻译： 式的化合物可用于抑制动物中的基质金属蛋白酶，因此预防和治疗由结缔组织破裂引起的疾病。 还公开了制备这些化合物的方法，包括其的药物组合物，以及治疗其中涉及基质金属蛋白酶的疾病的方法，包括多发性硬化，动脉粥样硬化斑块破裂，再狭窄，主动脉瘤，心力衰竭，牙周病，角膜溃疡， 烧伤，褥疮性溃疡，慢性溃疡或创伤，癌症转移，肿瘤血管发生，骨质疏松症，类风湿性关节炎，骨关节炎，肾脏疾病，左心室扩张或依赖于白细胞组织侵袭的其他自身免疫性或炎性疾病。

    Chromone derivatives as matrix metalloproteinase inhibitors
    6.
    发明授权
    Chromone derivatives as matrix metalloproteinase inhibitors 失效
    色酮衍生物作为基质金属蛋白酶抑制剂

    公开(公告)号：US06908917B2

    公开(公告)日：2005-06-21

    申请号：US10634718

    申请日：2003-08-05

    申请人： Daniel Fred Ortwine

    发明人： Daniel Fred Ortwine

    IPC分类号： A61K31/353 ,  A61K31/536 ,  A61P1/02 ,  A61P1/04 ,  A61P9/04 ,  A61P9/10 ,  A61P11/06 ,  A61P17/06 ,  A61P19/02 ,  A61P19/10 ,  A61P25/00 ,  A61P29/00 ,  C07D265/22 ,  C07D311/22 ,  A61K31/352 ,  A61K19/02

    CPC分类号： C07D311/22 ,  C07D265/22

    摘要： This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof, wherein R1, Q, Y2, Y3, Y4, U5, U6, U8, and R2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.

    摘要翻译： 本发明提供由式I定义的化合物或其药学上可接受的盐，其中R 1，Q，Y 2，Y 3，Y 3， SUP> 4，U 5，U 6，U 8，R 2和R 2分别为 在规范中定义。 本发明还提供药物组合物，其包含本说明书中定义的式I化合物或其药学上可接受的盐以及药学上可接受的载体，稀释剂或赋形剂。 本发明还提供了在动物中抑制MMP-13酶的方法，包括向动物施用式I化合物或其药学上可接受的盐。 本发明还提供了治疗患者中由MMP-13酶介导的疾病的方法，包括单独或在药物组合物中向患者施用式I化合物或其药学上可接受的盐。 本发明还提供了治疗诸如心脏病，多发性硬化，骨关节炎和类风湿性关节炎，除了骨关节炎或类风湿性关节炎之外的关节炎，心功能不全，炎性肠病，心力衰竭，年龄相关性黄斑变性，慢性阻塞性肺 疾病，哮喘，牙周疾病，牛皮癣，动脉粥样硬化和骨质疏松症，其包括单独或在药物组合物中向患者施用式I化合物或其药学上可接受的盐。 本发明还提供了包含式I化合物或其药学上可接受的盐以及说明书中描述的另一种药学活性成分的组合。